FibroGen: Pamrevlumab Gets FDA's Fast Track Designation To Treat Duchenne Muscular Dystrophy

colon lt

Biotech company FibroGen Inc. (FGEN) announced Monday that the U.S. Food and Drug Administration has granted Fast Track designation for the company's anti-CTGF antibody, pamrevlumab, for the treatment of patients with Duchenne muscular dystrophy or DMD.

In pre-market activity on Nasdaq, FibroGen shares were gaining around 4 percent to trade at $19.30.

The company said the latest FDA designation follows review of the Phase 2 clinical data from a single-arm trial in non-ambulatory patients with DMD. It represents recognition by the FDA that pamrevlumab has the potential to address an unmet medical need for this disease.

Fast Track designation is intended to facilitate the development and review of drugs used to treat serious conditions and to fill an unmet medical need.

Pamrevlumab is a first-in-class antibody developed by FibroGen that inhibits the activity of connective tissue growth factor, an important biological mediator in fibrotic and proliferative disorders.

Pamrevlumab is currently being evaluated in two Phase 3 trials for the treatment of DMD.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Southwest Airlines' flights across the United States were delayed for hours on Monday evening due to technical issue in a weather information system by a third-party weather data provider. The airline later resumed flight operations after solving the issue, but there were delays. The United Kingdom's Competition and Markets Authority or CMA announced Tuesday that it has launched a market study into mobile ecosystems of technology giants Apple Inc. (AAPL) and Google, Inc. (GOOG) over concerns they have market power which is harming users and other businesses. The CMA is taking... Eli Lilly and Co. (LLY) announced Tuesday that it will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant), an orally disintegrating tablet patients take every other day. This study will help to advance the science of migraine treatment...
Follow RTT